Skip to content
DataLookout
Start free
Menu

ClinicalTrials.gov term: Lymphoma, Follicular

Follicular Lymphoma clinical trials

Get alerts when Follicular Lymphoma trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-05

What changed in the last 30 days

32 trials changed in the last 30 days: 1 stopped, 15 with notable changes, 16 with minor changes only.

  1. Notable: Auto Stem Cell Transplant for Lymphoma Patients Primary completion pushed from Sep 30, 2026 to Sep 30, 2027 Masonic Cancer Center, University of MinnesotaPhase 2 NCT03125642
  2. Minor: Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body · B-Cell Malignancies Trial arms changed: 4 → 1 AbbViePhase 1 NCT05753501
  3. Minor: SIDNEY · Novel Vaccine (EO2463) as Monotherapy and in Combination, · Indolent Non-Hodgkin Lymphoma Enrollment closed, study ongoing EnteromePhase 1/2 NCT04669171
  4. Minor: CAN3001 · PCI-32765 (Ibrutinib) Trial sites reduced: 175 → 156 locations Janssen Research & Development, LLCPhase 3 NCT01804686
  5. Notable: Copanlisib and Nivolumab · Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma Primary and study completion pushed from Nov 4, 2026 to Oct 7, 2027 City of Hope Medical CenterPhase 1 NCT03884998
  6. Minor: WaveSpan-008 · MK-1045 · Non-Hodgkin Lymphoma (MK-1045-008) Trial sites expanded: 49 → 52 locations Merck Sharp & Dohme LLCPhase 1/2 NCT07519772
  7. Notable: Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment Primary completion pushed from Dec 31, 2026 to Dec 1, 2029 SWOG Cancer Research NetworkPhase 2 NCT05890352
  8. Notable: CS22-03 · People Living With HIV Treated With CD19-directed CAR T Cell Results posted: Oct 28, 2026 AIDS Malignancy ConsortiumNot specified NCT05784415
  9. Notable: Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma Results posted: Oct 28, 2026 Washington University School of MedicinePhase 2 NCT05410418
  10. Minor: MDX2003 · Different Types of Lymphoma Trial sites expanded: 2 → 6 locations ModeX Therapeutics, An OPKO Health CompanyPhase 1/2 NCT07249905
  11. Minor: MK-1045 and Rituximab · Follicular Lymphoma (MK-1045-007) Trial sites expanded: 32 → 35 locations Merck Sharp & Dohme LLCPhase 2/3 NCT07634471
  12. Minor: Rituximab and Mosunetuzumab Drug Treatments · Low Tumor Burden Follicular Lymphoma Trial sites expanded: 285 → 288 locations National Cancer Institute (NCI)Phase 3 NCT06337318
  13. Minor: Cellular Immunotherapy Following Chemotherapy · Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia Start date pushed from Sep 24, 2014 to Oct 14, 2014 City of Hope Medical CenterPhase 1 NCT02153580
  14. Minor: Selinexor Plus Combination Chemotherapy · Advanced B Cell Non-Hodgkin Lymphoma Primary and study completion moved earlier from Dec 2027 to Jun 25, 2027 Barbara Ann Karmanos Cancer InstitutePhase 1/2 NCT03147885
  15. Minor: Rituximab and Pembrolizumab With or Without Lenalidomide · Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Study completion pushed from Apr 30, 2026 to Apr 30, 2030 M.D. Anderson Cancer CenterPhase 2 NCT02446457
  16. Notable: Treatment · B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader Sponsor changed: BeiGene to BeOne Medicines BeOne MedicinesPhase 1/2 NCT05294731
  17. Minor: Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients Trial sites expanded: 235 → 244 locations AstraZenecaPhase 3 NCT06549595
  18. Notable: TOP-FLOR · Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab Primary completion pushed from Jan 1, 2027 to Jan 1, 2028 Olivia Newton-John Cancer Research InstitutePhase 2 NCT05788081
  19. Minor: FLUORO · Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy Study completion pushed from Jul 2025 to Jul 2027 Olivia Newton-John Cancer Research InstitutePhase 2 NCT04962126
  20. Notable: Tafasitamab and Rituximab · Newly Diagnosed Follicular Lymphoma Recruitment opened University of WashingtonPhase 2 NCT07731789
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-10-15 NCT07875413 Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory… AbelZeta Inc. new Phase 2

Active trials by phase

Early Phase 1
2
Phase 1
71
Phase 1/2
46
Phase 2
95
Phase 2/3
3
Phase 3
27
Not charted: 52 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Top sponsors by active trials in this area

City of Hope Medical Center (14) · National Cancer Institute (NCI) (11) · M.D. Anderson Cancer Center (9) · Fondazione Italiana Linfomi - ETS (7) · University of Washington (7) · Genmab (5) · Mayo Clinic (5) · Sun Yat-sen University (5) · AbbVie (4) · AstraZeneca (4)

Get alerts when Follicular Lymphoma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free